Cheaper cancer drug copy tested in melanoma trial – but study halted early
NCT ID NCT06587451
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a biosimilar (JPB898) against the original immunotherapy Opdivo, both combined with Yervoy, in 52 adults with advanced melanoma that could not be surgically removed. The goal was to see if the biosimilar works just as well. However, the trial was terminated early, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab biosimilar (JPB898) plus ipilimumab (Yervoy)
What this could lead to
If successful, this could show that a more affordable biosimilar works as well as the original drug for advanced melanoma.
What could go wrong
The trial was terminated early with only 52 participants, so results are limited. Biosimilars may not always match the original drug's effectiveness or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sandoz Investigational Site
Santiago, Chile
-
Sandoz Investigational Site
Athens, Greece
-
Sandoz Investigational Site
Thessaloniki, Greece
-
Sandoz Investigational Site
Pisa, Italy
-
Sandoz Investigational Site
Vilnius, Lithuania
-
Sandoz Investigational Site
Kuala Lumpur, Malaysia
-
Sandoz Investigational Site
Pulau Pinang, Malaysia
-
Sandoz Investigational Site
Putrajaya, Malaysia
-
Sandoz Investigational Site
Bacolod, Philippines
-
Sandoz Investigational Site
Warsaw, Poland
-
Sandoz Investigational Site
Lisbon, Portugal
-
Sandoz Investigational Site
Daejeon, South Korea
-
Sandoz Investigational Site
Málaga, Spain
-
Sandoz Investigational Site
Oviedo, Spain
-
Sandoz Investigational Site
Santander, Spain
-
Sandoz Investigational Site
Santiago de Compostela, Spain
-
Sandoz Investigational Site 1
Santiago, Chile
-
Sandoz Investigational Site 1
Busan, South Korea
-
Sandoz Investigational Site 2
Tbilisi, Georgia
-
Sandoz Investigational Site 2
Seoul, South Korea
-
Sandoz Investigational Site 2
Madrid, Spain
-
Sandoz Investigational Site 2
Valencia, Spain